Document Detail


Phase I study of neocarzinostatin in children with cancer.
MedLine Citation:
PMID:  156067     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Twenty-three children with advanced cancer refractory to conventional therapy received weekly iv doses of neocarzinostatin for 5 weeks. Doses were escalated from 500 to 6750 units/m2/week. Four types of toxic manifestations occurred: acute reactions consisting of shaking chills with or without fever and cyanosis (rigor), hypersensitivity, vomiting, and marrow depression. Evidence of oncolytic activity was limited to patients with acute leukemia in whom phase II trials at doses between 3000 and 4500 units/m2 appear warranted.
Authors:
G Rivera; C Howarth; R J Aur; C B Pratt
Related Documents :
3798127 - Appetite stimulation with megestrol acetate in cachectic cancer patients.
8336187 - All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome.
9816117 - Phase i trial of the thymidylate synthase inhibitor ag331 as a 5-day continuous infusion.
12176787 - Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomi...
11317337 - Comparison of hprt and laci mutant frequency with dna adduct formation in n-hydroxy-2-a...
8742497 - Effects of a newly developed transdermal clonidine delivery system (m-5041t) on eeg sle...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Cancer treatment reports     Volume:  62     ISSN:  0361-5960     ISO Abbreviation:  Cancer Treat Rep     Publication Date:  1978 Dec 
Date Detail:
Created Date:  1979-08-16     Completed Date:  1979-08-16     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7607107     Medline TA:  Cancer Treat Rep     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  2105-7     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Antibiotics, Antineoplastic / pharmacology*
Bone Marrow / drug effects
Child
Child, Preschool
Drug Evaluation
Drug Hypersensitivity
Humans
Infant
Leukemia, Lymphoid / drug therapy*
Leukemia, Myeloid, Acute / drug therapy
Neoplasms / drug therapy*
Remission, Spontaneous
Shivering / drug effects
Vomiting / chemically induced
Zinostatin / pharmacology*,  toxicity
Chemical
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 9014-02-2/Zinostatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Experimental and clinical studies on the formation of antibodies to neocarzinostatin, a new protein ...
Next Document:  Preliminary evaluation of 15 chemotherapeutic agents applied topically in the treatment of mycosis f...